The FDA announced on September 25, 2015, that Boehringer Ingelheim Roxane Inc voluntarily recalled Furosemide Tablets USP, 20 mg due to CGMP deviations involving the inadvertent use of an active pharmaceutical ingredient intended for oral solution. The recall affects 11,110 bottles distributed nationwide and in Puerto Rico.
How to tell if you have it
- Brand: Boehringer Ingelheim Roxane
- Product: Furosemide Tablets USP, 20 mg, 1000-count bottle
- NDC: 0054-4297-31
- UPC: 3 0054-4297-31 8 (or 00300544297318)
- Lot codes: 559660P, 559661P
- Expiration date: 03/17
The hazard
The firm used the active pharmaceutical ingredient intended for furosemide oral solution USP to manufacture the recalled tablets. This constitutes a CGMP deviation.
Context
GovInfoNow's records show Boehringer Ingelheim Roxane Inc has 12 other recalls on record since 2012-11-05. Other recent recalls of similar products include Combivent Respimat Recall (2015-07-24), Roxane Recalls Acarbose 50mg Tablets Due to Low Potency (2015-04-02), and Roxane Recalls Oxycodone Oral Solution Due to Stability Failure (2014-07-28). Other recent recalls of similar products include Leading Pharma Recalls Furosemide 80mg Due to Impurity (2026-03-20) and Wells Pharma fentanyl injectable solution recall due to manufacturing deviations (2026-04-01).